Royalty Report: Drugs, Therapeutic, Antibody – Collection: 227230

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Antibody
  • Diagnostic
  • Disease
  • DNA
  • Alzheimer’s disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 227230

License Grant
The Licensor, co-coordinating and funding medical research in the United Kingdom, agrees to grant to the Licensee the following licenses under the Winter Patent
(i)  a non-exclusive worldwide license to exploit the Winter Patent commercially in any way whatsoever by the use of the Reshaping Process in the Fields and by the commercial exploitation in the Fields of any resulting antibodies provided always that any such exploitation does not involve the antibodies detailed in the agreement hereto; and (ii) a non-exclusive sublicense under the Boss Patents to the extent required to enable the licensee to use the Reshaping Process in accordance with (i) above and for no other purpose.

The Licensee shall not be entitled to grant sublicenses of the rights granted to it under this Agreement except with the prior written consent of Licensor. The licensee shall use its best endeavors to ensure that any sublicensee performs its obligations under any such sublicense.

License Property
The Reshaping Process shall mean the genetic engineering of monoclonal antibodies comprising the  replacement, in whole or in part, of the complementarity determining regions of one antibody by those of another as described in the Winter Patent.

The Boss Patents shall mean
               (i)  European Patent Application 0 120 693 (84301996.9) of 23 March 1984 naming Michael Alan Boss as an inventor;
               (ii) GB Patent Application 8308235 of 25 March 1983;
               (iii) Japanese Patent Application 501609/84 of 23 March 1984;
               (iv) and any patent granted or to be granted on such patent application(s).
               (v)  US Patent 4 816 397 of 28 March 1989.

4,816,397 – Multichain polypeptides or proteins and processes for their production

The Products shall mean products produced either directly or indirectly from antibodies which have been modified using the Reshaping Process and which are in a form capable of being marketed or sold upon a commercial basis (the parties intend that the Products will include in some manner such an antibody).

Field of Use
Fields shall mean the field of human therapy and human in vivo and in vitro diagnostics.

License permits Licensee to humanize our murine monoclonal antibodies.

IPSCIO Record ID: 240466

License Grant
The Licensor of England grants to the Licensee the following licenses under the Winter Patent
– a non-exclusive world-wide license to exploit the Winter Patent commercially in any way whatsoever by the use of the Reshaping Process in the Fields and by the commercial exploitation in the Fields of any resulting antibodies provided always that any such exploitation does not involve the antibodies detailed.
– a non-exclusive sub-license under the Boss Patents to the extent required to enable the licensee to use the Reshaping Process to produce Products from mammalian cells and for no other purpose.
License Property
Licensor has certain patent rights in respect of the genetic engineering of monoclonal antibodies comprising the replacement in whole or in part of the complementarity determining regions of one antibody by those of another.

The Reshaping Process shall mean the genetic engineering of monoclonal antibodies comprising the replacement in whole or in part of the complementarity determining regions of one antibody by those of another as described in the Winter Patent.

The Products shall mean end products produced either directly or indirectly from antibodies which have been modified using the Reshaping Process and which are in a form capable of being marketed or sold upon a commercial basis.

Winter patents relate to Recombinant DNA products and Methods.

Boss patents relate to Multichain Polypeptides or Proteins and Processes for their Production Expression of multichain proteins, such as antibodies, in single hose cells.

Field of Use
The Fields shall mean the field of human therapy or prophylaxis and human in vivo and in vitro diagnostics.

IPSCIO Record ID: 203270

License Grant
The English Licensor grants (i) a non-exclusive worldwide sublicense, with the right to grant further Sublicenses, under the Licensed Patent Rights to make, have made, use, import, offer for sale, and/or sell Licensed Products; and (ii) an exclusive worldwide license, with the right to grant Sublicenses, under the Licensors Intellectual Property, to make, have made, use, import, offer for sale, and/or sell Licensed Products.

Licensee shall be entitled to grant further non-exclusive Sublicenses to its Licensees to make, have made, use, import, offer for sale, and/or sell Licensed Products.

License Property
The Licensed Product shall mean a product comprising a Humanised Antibody, the manufacture, use, offer for sale, sale, or importation of which by an unlicensed third party would infringe one or more Valid Claims of the Licensed Patent Rights, or which incorporates Licensors Intellectual Property or Inventions, not including chimeric antibodies or murine antibodies.

The patents are for Recombinant DNA Products and Methods and Multichain Polypeptides or Proteins and Processes for their Production.

Licensor has genetic engineering expertise to modify murine antibodies wherein certain regions of the immunoglobulin are changed from mouse to human, which modification is sometimes, in one aspect, referred to as humanising or humanisation.

The Antibody are either Antibody IN-NO1 or Antibody IN-C02 and Antibodies shall mean both Antibody IN-NO1 and Antibody IN-C02.

Field of Use
Two companies have entered into an agreement under which Licensor will use its proprietary technology and advanced know-how to humanize Intellect's beta-amyloid specific, monoclonal antibodies for the treatment of Alzheimer's disease. The antibodies are intended as a form of passive immunization to promote clearance from the brain of the endogenous soluble Alzheimer's toxin, beta-amyloid, where it accumulates and causes devastating damage to victims of the disease. Humanization is an essential step in making antibodies safe for use in humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.